Stockscreener 앱 받기
18.25
1.76%
-0.3693
전일 마감가:
$18.62
열려 있는:
$18.4
하루 거래량:
554.72K
Relative Volume:
0.24
시가총액:
$3.55B
수익:
$1.14B
순이익/손실:
$-250.98M
주가수익비율:
-13.42
EPS:
-1.36
순현금흐름:
$-251.61M
1주 성능:
-2.58%
1개월 성능:
-1.87%
6개월 성능:
+0.72%
1년 성능:
-42.30%
1일 변동 폭
$17.92
$18.49
1주일 범위
$17.92
$19.25
52주 변동 폭
$16.24
$37.50
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Compare LEGN vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
18.24 | 3.72B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
507.77 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.57 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
766.56 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.19 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
190.52 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 다운그레이드 | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-01-07 | 개시 | Oppenheimer | Outperform |
| 2025-10-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-06-17 | 개시 | Truist | Buy |
| 2024-05-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-05-23 | 개시 | Deutsche Bank | Buy |
| 2024-04-17 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | Raymond James | Outperform |
| 2023-12-19 | 개시 | Scotiabank | Sector Perform |
| 2023-11-06 | 개시 | Goldman | Buy |
| 2023-05-25 | 개시 | William Blair | Mkt Perform |
| 2023-05-22 | 개시 | Daiwa Securities | Buy |
| 2023-03-29 | 개시 | H.C. Wainwright | Buy |
| 2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-11-02 | 개시 | Evercore ISI | Outperform |
| 2022-11-01 | 개시 | Cowen | Outperform |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-03-15 | 개시 | Barclays | Overweight |
| 2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-07-01 | 개시 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
Legend Biotech launches grant program for myeloma research - Investing.com
Legend Biotech Corporation (LEGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright reiterates Legend Biotech stock rating on durability data - Investing.com
ETFs Investing in Legend Biotech Corp. Sponsored ADR Stocks - TradingView
Preferred dividends of Legend Biotech Corp. Sponsored ADR – HAN:9LB - TradingView
Legend Biotech Corp. Sponsored ADR Statistics – HAN:9LB - TradingView
Form 4 Legend Biotech Corp For: 29 September - Investing.com India
Form 144 Legend Biotech Corp For: 27 September By Investing.com - Investing.com Nigeria
Form 144 Legend Biotech Corp For: 27 September - Investing.com India
Legend Biotech reports 5-year CARVYKTI data in myeloma patients - Investing.com
Legend Biotech CFO Carlos E. Santos Reports Share Acquisition and Sale on September 21, 2026 - Kalkine Media
Form 4 Legend Biotech Corp For: 23 September By Investing.com - Investing.com India
Legend Biotech CFO Carlos Santos sells $49,630 in shares - Investing.com
Form 144 Legend Biotech Corp For: 22 September By Investing.com - Investing.com India
Legend Biotech CEO Ingrid Zhang Granted 1.13 Million RSUs with Three-Year Vesting - Kalkine Media
Data on five-year remission with a myeloma treatment will be presented in Scotland - Stock Titan
H.C. Wainwright reiterates Legend Biotech stock rating at buy - investing.com
Legend Biotech (LEGN) Institutional Ownership 2026 - MarketBeat
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards - Stock Titan
Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade - MarketBeat
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns - Investing.com
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings - MarketBeat
Why is Legend Biotech stock surging today? By Investing.com - Investing.com South Africa
Legend Biotech Q2 2026 slides: first profitable quarter, 50% growth - Investing.com
Legend Biotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5% - Investing.com
Why is Legend Biotech stock surging today? - Investing.com
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com South Africa
Legend Biotech stock rises 5% on earnings and revenue beat - Investing.com
Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing? - Kalkine Media
Legend Biotech in spotlight: Earnings test Carvykti momentum - Investing.com
1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A. - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sei Investments Co. Buys 221,899 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
Renaissance Technologies LLC Purchases 119,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
H.C. Wainwright reiterates Buy on Legend Biotech stock at $65 - Investing.com
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim By Investing.com - Investing.com South Africa
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim - Investing.com
RBC cuts Legend Biotech stock price target to $59 on model updates - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns By Investing.com - Investing.com India
Legend Biotech (NASDAQ:LEGN) Stock Price Up 6.8%Here's Why - MarketBeat
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.26%
0.58%
자본화:
|
볼륨(24시간):